Cohort of Patients With Fatty Liver Disease

Overview

Información sobre este estudio

The purpose of this research is to create a registry of patients having or at risk for metabolic liver disease for investigations into the molecular pathogenesis of cirrhosis, liver cancer, and end-stage liver disease.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Males and females who are 18 years of age or older.
  • Have radiographically or pathologically confirmed diagnosis of NASH or a newly diagnosed fatty liver or identified to have elevated liver enzymes.
  • Does not have a diagnosis of HIV or AIDS.
  • Do not have a diagnosis of other etiologies of liver cancer (e.g., viral hepatitis B or C, alcoholic liver disease, alcohol abuse, or rare genetic syndromes that predisposes to liver cancer).
  • Are compos mentis: of sound mind, memory and understanding, and able to provide written informed consent.

Exclusion Criteria:

  • Is under the age of 18 years or over the age of 100 years.
  • Is not mentally competent to provide consent.
  • Has been diagnosed with post-traumatic stress disorder(PTSD).
  • Has a diagnosis of HIV or AIDS.
  • Is institutionalized (e.g., FMC patients or nursing home).
  • Has a diagnosis of any of the following conditions:
    • History of hepatitis B or C virus (HBV, HCV) infections;
    • History of alcoholic liver disease or alcohol abuse;
    • Autoimmune hepatitis;
    • Alpha-1-antitrypsin deficiency;
    • Hemochromatosis;
    • Wilson’s disease;
    • Biliary cirrhosis;
    • Consume ≥ 20 grams of alcohol/day or > 1 drink/day for women and > 2 drinks/day.
    • Stage 4 fibrosis (i.e. cirrhosis)
    • Any cancer

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/19/24. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Samuel Antwi, Ph.D.

Abierto para la inscripción

Contact information:

Maria Caruso

(904) 953-0637

FLAQHSCS@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20543850

Mayo Clinic Footer